Press Releases

GWOXI Stem Cell announced today that through an innovative industry-academia collaboration, it has obtained a Taiwan invention patent titled "Pharmaceutical Composition Comprising Adipose Tissue-Derived Extracellular Vesicles and Biologics, and Uses for Treating Arthritis." The patent provides a pharmaceutical composition containing adipose tissue-derived extracellular vesicles and biologics for the treatment of arthritis, marking a breakthrough development in the treatment of rheumatoid arthritis.

 

There are approximately 355 million people worldwide living with arthritis, with over 100 million in China alone. In the United States, one in five people experiences pain and discomfort caused by arthritis. In Asia, one in six people develops the disease at some point in their lifetime. Moreover, arthritis is not a condition exclusive to the elderly—it affects people of all age groups, including children.

 

According to the National Health Insurance Database, rheumatoid arthritis (RA) is an autoimmune disease that can affect the entire body or specific joints. Epidemiological studies indicate that the global prevalence among adults is approximately 1%. However, rheumatoid arthritis is a lifelong condition that can significantly impair patients’ physical function and mobility.

 

According to the National Health Insurance Database, rheumatoid arthritis (RA) is an autoimmune disease that can affect the entire body or specific joints. Epidemiological studies indicate that the global prevalence among adults is approximately 1%. However, rheumatoid arthritis is a lifelong condition that can significantly impair patients’ physical function and mobility.

 

The patent for “pharmaceutical compositions comprising extracellular vesicles isolated from adipose tissue and biologics, and their use in the treatment of arthritis” is based on a formulation that utilizes extracellular vesicles from adipose tissue and biologics to suppress and regulate the inflammatory cytokines IL-17 and IL-22 produced by Th17 cells derived from blood, thereby reducing the excessive activation of osteoclasts.

 

Research data from the Ministry of Health and Welfare indicate that the main culprit in autoimmune inflammation is IL-17A (Interleukin-17A), which is associated with the overexpression of pro-inflammatory cytokines and is a member of the IL-17 cytokine family. Exosome-based therapy can help alleviate pain and functional impairment in the affected areas of patients with rheumatoid arthritis.

 

GWOXI focuses on the development of stem cell-based therapeutics, with technology spanning the upstream, midstream, and downstream sectors of the regenerative medicine industry. Committed to innovation and research, the company continuously invests in R&D and has successfully achieved multiple forward-looking research milestones. Valuing both technology and talent, GWOXI plans to continue using Taiwan as its R&D base, leveraging strategic patent filings to create additional niche market opportunities.